RENal hemodialysis patients ALlocated apixaban versus warfarin in Atrial Fibrillation (RENAL-AF)
Principal Investigator: Vimal Derebail, MD, MPH
Sponsors: Duke University Medical Center; Bristol-Myers Squibb Company
Age Range: 18+
Status: Starting soon
Purpose: This study will determine the safety of using blood thinners in patients with atrial fibrillation and on hemodialysis and will compare apixaban, a newer blood thinner, against warfarin, a traditional blood thinner.
Study Procedures: After a screening visit at UNC you will be randomized to take either apixaban or warfarin. The screening visit involves an ECG, drawing blood samples, and reviewing your medical history. Follow-up visits can occur at dialysis centers and involve monitoring your health, reviewing your medications, and drawing blood samples.
Participation: You will be in this study up to 15 months after your first visit.
For more information, please contact: